Exa Capital acquires StaffReady
March 2026—Exa Capital has acquired StaffReady, an SaaS platform for managing clinical workforces in health care.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
BD launches new FacsDiscover A8 configurations
February 2026—BD released new configurations of its FacsDiscover A8 cell analyzers.
Octave, Quest expand access to Octave MSDA test
February 2026—Octave Bioscience is collaborating with Quest Diagnostics to make the Octave Multiple Sclerosis Disease Activity test accessible through Quest’s nationwide specimen-collection network.
Natera acquires Foresight Dx
February 2026—Natera has completed a transaction to acquire cancer diagnostics company Foresight Diagnostics.
Randox type 1 diabetes risk test gets CE mark
February 2026—Randox’s type 1 diabetes risk test has received CE marking.
Revvity launches somatic cancer reference standards
February 2026—Revvity launched highly characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium and National Institute of Standards and Technology as part of the Somatic Reference Samples Initiative.
CellaVision bone marrow aspirate application gets CE mark
February 2026—CellaVision’s bone marrow aspirate application has received the CE mark as a class C product under the European Union in vitro diagnostic regulation.
Fujifilm and Voicebrook partner
February 2026—Fujifilm Healthcare Americas Corp. and Voicebrook are partnering to integrate Voicebrook’s VoiceOver Pro with Fujifilm’s Synapse Pathology, a picture archiving and communication system designed to streamline case management.
Volta Labs adds WGS apps to Callisto platform
February 2026—Volta Labs is expanding its Callisto sample preparation platform by adding seven validated whole genome sequencing DNA apps.
Illumina gets CMS reimbursement for TSO Comprehensive
February 2026—Illumina announced that reimbursement has been granted for its FDA-approved in vitro diagnostic TruSight Oncology Comprehensive test.